ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?
- PMID: 30809027
- DOI: 10.1038/s41571-019-0191-7
ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?
Comment on
-
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources